Recombinant Type III Humanized Collagen Solution for Injection Promotes Skin Repair in Chinese Population: A Case Series

IF 2.3 4区医学 Q2 DERMATOLOGY

Journal of Cosmetic Dermatology Pub Date : 2025-05-25 DOI:10.1111/jocd.70226

Xiaoguang Duan, Chunmei Ding, Jiewei Wu, Weiwei Bao, Yu Gao, Fei Liu, Wei Cai

{"title":"Recombinant Type III Humanized Collagen Solution for Injection Promotes Skin Repair in Chinese Population: A Case Series","authors":"Xiaoguang Duan, Chunmei Ding, Jiewei Wu, Weiwei Bao, Yu Gao, Fei Liu, Wei Cai","doi":"10.1111/jocd.70226","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Facial erythema and acne scarring are common skin conditions that significantly impair quality of life, necessitating effective treatment options, particularly in Asian populations.</p>\n </section>\n \n <section>\n \n <h3> Aims</h3>\n \n <p>To evaluate the efficacy and safety of intradermal injections of recombinant type III humanized collagen (RhCol-III) solution for alleviating facial erythema, improving skin texture associated with acne scarring, and evening out skin tone issues associated with post-inflammatory hyperpigmentation (PIH) from acne while also searching for potential underlying anti-inflammatory mechanisms of the RhCol-III solution.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This case series included six Chinese participants with Fitzpatrick phototypes III/IV, presenting with facial erythema and/or acne scarring. Participants received intradermal injections of 2 mg/mL RhCol-III solution at baseline, 30- and 60- days post-baseline. Clinical evaluations were conducted using VISIA photography and self-assessed Global Aesthetic Improvement Scale (GAIS) scores. Additionally, in vitro testing was performed using the U937 cell line with lipopolysaccharide (LPS) induction to assess the anti-inflammatory effects of the RhCol-III solution on tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) secretion.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>All participants demonstrated a reduction in facial erythema post-treatment, with significant improvements noted in the zygomatic area. The mean erythema area decreased by 49.3% after 90 days. One case with acne scarring showed visible improvement in scar appearance, skin tone, and texture. Moreover, 0.10 mg/mL RhCol-III solution significantly reduced TNF-α and IL-6 levels in vitro by up to 47.75% and 44.96%, respectively.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>RhCol-III solution injections effectively reduced facial erythema and have the potential to improve acne scarring via reduction in the extent of PIH in this series of Chinese cases. The treatment was well-tolerated, with no significant adverse effects. These findings suggest RhCol-III solution as a promising therapeutic option for skin repair and inflammation reduction.</p>\n </section>\n </div>","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":"24 5","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jocd.70226","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cosmetic Dermatology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jocd.70226","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Facial erythema and acne scarring are common skin conditions that significantly impair quality of life, necessitating effective treatment options, particularly in Asian populations.

Aims

To evaluate the efficacy and safety of intradermal injections of recombinant type III humanized collagen (RhCol-III) solution for alleviating facial erythema, improving skin texture associated with acne scarring, and evening out skin tone issues associated with post-inflammatory hyperpigmentation (PIH) from acne while also searching for potential underlying anti-inflammatory mechanisms of the RhCol-III solution.

Methods

This case series included six Chinese participants with Fitzpatrick phototypes III/IV, presenting with facial erythema and/or acne scarring. Participants received intradermal injections of 2 mg/mL RhCol-III solution at baseline, 30- and 60- days post-baseline. Clinical evaluations were conducted using VISIA photography and self-assessed Global Aesthetic Improvement Scale (GAIS) scores. Additionally, in vitro testing was performed using the U937 cell line with lipopolysaccharide (LPS) induction to assess the anti-inflammatory effects of the RhCol-III solution on tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) secretion.

Results

All participants demonstrated a reduction in facial erythema post-treatment, with significant improvements noted in the zygomatic area. The mean erythema area decreased by 49.3% after 90 days. One case with acne scarring showed visible improvement in scar appearance, skin tone, and texture. Moreover, 0.10 mg/mL RhCol-III solution significantly reduced TNF-α and IL-6 levels in vitro by up to 47.75% and 44.96%, respectively.

Conclusion

RhCol-III solution injections effectively reduced facial erythema and have the potential to improve acne scarring via reduction in the extent of PIH in this series of Chinese cases. The treatment was well-tolerated, with no significant adverse effects. These findings suggest RhCol-III solution as a promising therapeutic option for skin repair and inflammation reduction.

查看原文本刊更多论文

注射用重组III型人源胶原蛋白溶液促进中国人皮肤修复：一个案例系列

面部红斑和痤疮疤痕是严重影响生活质量的常见皮肤病，需要有效的治疗选择，特别是在亚洲人群中。目的评价重组III型人源胶原（RhCol-III）溶液皮内注射对缓解面部红斑、改善痤疮瘢痕相关皮肤质地的疗效和安全性。消除与痤疮引起的炎症后色素沉着（PIH）相关的肤色问题，同时寻找RhCol-III溶液潜在的潜在抗炎机制。方法本病例系列包括6例中国患者，Fitzpatrick光型III/IV型，表现为面部红斑和/或痤疮疤痕。参与者在基线、基线后30天和60天接受2mg /mL RhCol-III溶液皮内注射。临床评估采用VISIA摄影和自我评估的全球审美改善量表（GAIS）评分进行。此外，采用脂多糖（LPS）诱导U937细胞系进行体外实验，评估RhCol-III溶液对肿瘤坏死因子-α (TNF-α)和白细胞介素-6 （IL-6）分泌的抗炎作用。结果：所有参与者在治疗后面部红斑均有所减轻，颧骨区域有显著改善。90 d后平均红斑面积减少49.3%。一例痤疮疤痕在疤痕外观、肤色和质地上有明显改善。此外，0.10 mg/mL RhCol-III溶液可显著降低体外TNF-α和IL-6水平，分别达到47.75%和44.96%。结论RhCol-III溶液注射可有效减轻面部红斑，并有可能通过减少PIH程度来改善痤疮疤痕。治疗耐受性良好，无明显不良反应。这些发现表明RhCol-III溶液是修复皮肤和减少炎症的有希望的治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Cosmetic Dermatology DERMATOLOGY-

CiteScore

4.30

自引率

13.00%

发文量

818

审稿时长

>12 weeks

期刊介绍： The Journal of Cosmetic Dermatology publishes high quality, peer-reviewed articles on all aspects of cosmetic dermatology with the aim to foster the highest standards of patient care in cosmetic dermatology. Published quarterly, the Journal of Cosmetic Dermatology facilitates continuing professional development and provides a forum for the exchange of scientific research and innovative techniques. The scope of coverage includes, but will not be limited to: healthy skin; skin maintenance; ageing skin; photodamage and photoprotection; rejuvenation; biochemistry, endocrinology and neuroimmunology of healthy skin; imaging; skin measurement; quality of life; skin types; sensitive skin; rosacea and acne; sebum; sweat; fat; phlebology; hair conservation, restoration and removal; nails and nail surgery; pigment; psychological and medicolegal issues; retinoids; cosmetic chemistry; dermopharmacy; cosmeceuticals; toiletries; striae; cellulite; cosmetic dermatological surgery; blepharoplasty; liposuction; surgical complications; botulinum; fillers, peels and dermabrasion; local and tumescent anaesthesia; electrosurgery; lasers, including laser physics, laser research and safety, vascular lasers, pigment lasers, hair removal lasers, tattoo removal lasers, resurfacing lasers, dermal remodelling lasers and laser complications.